Management – OLD


Steve Parkinson
Executive Director, Chief Executive Officer and President

Mr. Parkinson has more than 30 years of experience in the biopharmaceutical industry. As co-founder and CEO of TranXenoGen, Mr. Parkinson oversaw its IPO and admission to AIM in July of 2000, increasing its market value from $90M to $250M within one year.


As President and CEO of CereMedix, a drug discovery and development company, he advanced their first product to clinical trials. Mr. Parkinson has raised both public and private capital, built management teams, and managed M&A, in-licensed and out-licensed products/technology.


Mr. Parkinson has secured major industry contracts and collaborations for a number of companies, including Advanced Cell Technology where he was CEO, Johnson & Johnson, PPL Therapeutics, Genzyme Transgenics and Fermetech Ltd.

Peter F. Ceccacci
Chief Accounting Officer and VP Administration

Mr. Ceccacci brings a wealth of financial management leadership expertise, which includes an extensive career in public accounting with nearly 20 years spent as a Partner at several firms.  Most recently, he’s served as the CFO of a technology company, and has substantial experience in both the healthcare and technology sectors.


Mr. Ceccacci is an accomplished senior executive with comprehensive experience in accounting, finance, information systems, strategy, compliance and management.


Skilled in analytics, financial reporting, budgeting and projection modeling, Mr. Ceccacci brings a strategically-astute and results-driven business acumen to the company’s executive leadership team.

Michelle York Gocio
VP of Drug Development and Clinical Operations

Michelle York Gocio, Vice President of Drug Development and Clinical Operations, is a seasoned veteran of the pharmaceutical and biotechnology industry, having served 36 years in full scale development. Beginning her clinical research career in the neurosciences while still in college, Gociogradually expanded her interests and conducted trials in a wide variety of therapeutic indications,including pain, cancer pain, oncology, gastroenterology, ophthalmology, surgery,and antibiotic therapies.Her early work in the field of learning differences and ADD/ADHD is published inThe Journal of Learning Disabilities.During her career, Gocio has served in all roles, CRA through Vice President,and all phases of the development process, I-IV, prior to assuming her current role.


Ms.Gocio attended Northwestern University in Evanston, Illinois and graduated from the University of Arkansas at Little Rock with a major in Psychology and a minor in Biology. Additionally, Gocio has achieved certification as a Six Sigma Black Belt through the American Society of Quality. She has expanded the use of these engineering principles to drug development process to ensure operational excellence at Lakewood-Amedex Inc.

Dr. Kanneganti Murthy
Head of Preclinical Development

Dr. Murthy is a veteran molecular biologist and biochemist, with more than 20 years of experience and accomplishments in all phases of drug discovery and preclinical development from the identification of therapeutic targets, pharmacological profiling, and the progression of compounds through development.


Dr. Murthy joined Lakewood-Amedex in 2021 as Head of Preclinical Sciences. Recently, he served as Senior Director of Biology at Radikal/Salzman Group and was responsible for overseeing biology and preclinical efforts in the development of small molecules, peptides and proteins.


Dr. Murthy managed several preclinical programs to treat lung inhalation toxicity (antioxidants), multiple sclerosis (CXCL11), glaucoma (K-ATP channel modulator), and vitiligo (HSP70i). Before joining Radikal, he served as Director of Biology at Inotek Pharmaceuticals Corporation.


Dr. Murthy produced and patented novel broad-spectrum anti-flagellin human monoclonal antibodies to treat infectious diseases and led the Company’s poly (ADP-ribose) polymerase biology program, culminating in a multi-hundred-million-dollar strategic partnership with Genentech. His research efforts formed the basis for more than ten clinical programs. Dr. Murthy joined Inotek after a postdoctoral fellowship at Columbia University, New York.

Dr. Rich Paul
Chief Medical and Scientific Officer

Richard A. Paul, M.D., Chief Medical and Scientific Officer, is an actively licensed (FL and NJ) Internist with more than three decades of experience in new drug development, US and International regulatory affairs and clinical research. He attended the University of Miami and earned his M.D. Degree from the Faculty of Medicine at the University of Barcelona, Spain, Subsequently, Rich was elected as a Post-DoctoralResearch Fellow in Biochemistry and Enzymology at Albert Einstein School of Medicine, Bronx, NY and went on to complete his post graduate clinical medical training in Internal Medicine at a Rutgers University teaching hospital, Muhlenberg Regional Medical Center in Plainfield, NJ,where he was appointed Chief Medical Resident. Following completion of his residency he was accepted as an instructor in Medicine Fellow in Medicine, Diabetes, and associated Metabolic Diseases at the Joslin Diabetes Center at Harvard University’s School of Medicine. Thereafter, he worked as a teaching attending physicianat Morristown Memorial Hospital in Morristown, NJ and was appointed Associate Professor of Medicine,at Columbia University’s School of Medicine in NY. Following a decade of clinical practice in Diabetes and Metabolic Disease (children and adults), Dr. Paul was then invited to join Pfizer Pharmaceuticals’ Central Research Division in Groton, CT where he began an exciting career in translational drug development. Since, he has worked in and with other major pharmaceutical (Sandoz and Schering-Plough)and biotech companies helping to bring innovative drug products with various indications from the bench to the bedside. Over the years, Rich has also gained valuable experience in USA and international regulatory affairs and has had extensive experience as a Sponsor liaison in opening Investigator New Drug (IND) and CTA Applications to New Drug Applications (NDAs) ultimately leading to affirmative actions with several Divisions of the FDA. Rich currently resides in Lakewood Ranch, FL.

Kelvin Cooper
Executive Director Drug Development
Dr. Kelvin Cooper is a seasoned pharmaceutical scientist and executive with over 45 years’ experience in all aspects of drug discovery and development across a range of therapeutic areas including infectious disease, cancer, respiratory and immunology/inflammation.


Most recently Kelvin was an independent consultant with KC Pharma Consulting in areas such as portfolio analysis, process analysis, organizational analysis, software development and the interface between Artificial Intelligence and Drug Discovery.


Prior to that Kelvin worked at Pfizer in a number of roles including Senior Vice President for portfolio development in the Established Products Business Unit; Senior Vice President of Worldwide Pharmaceutical Sciences with responsibility for both small molecules and biologics in the areas of drug substance, drug product and device development; Executive Director of drug development for cancer, respiratory, allergy, immunology and infectious disease; and Director of drug discovery in those same therapeutic areas.


Kelvin earned a PhD in Organic Chemistry from the University of Nottingham, UK in 1982 and was awarded the Captain Black Award for Science. He has 46 publications and 34 patents.